Income statement
USD
Annual
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -188K | 0 | 0 | 0 | 0 |
| Operating Income | -45M | -34M | -18M | -16M | -19M |
| EBITDA | -43M | -32M | -17M | -16M | -19M |
| Net Income | -56M | -39M | -23M | -16M | -19M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00004
+0.00% today
1Y Change
-60.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TetraLogic Pharmaceuticals Corporation (TLOG) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 60.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -34.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -34.7%, free cash flow -6.3% with operating margin 0.0% and ROIC -74.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TLOG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLOG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TLOG Max Drawdown
-96.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TLOG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$18.9M
-16.3% YoY
Free Cash Flow
-$17.3M
-8.7% YoY
Revenue Growth
+0.0%
EPS Growth
-34.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -188K | 0 | 0 | 0 | 0 |
| Operating Income | -45M | -34M | -18M | -16M | -19M |
| EBITDA | -43M | -32M | -17M | -16M | -19M |
| Net Income | -56M | -39M | -23M | -16M | -19M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15M | 13M | 55M | 5M | 10M |
| Total Assets | 64M | 118M | 56M | 5M | 16M |
| Total Liabilities | 70M | 85M | 5M | 73M | 69M |
| Shareholder Equity | -6M | 33M | 51M | -68M | -53M |
| Total Debt | 28M | 29M | 0 | 5M | 0 |
| Net Debt | 13M | 16M | -55M | 244K | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17M
-8.8% YoY
Capital Expenditures
14K
+52.9% YoY
Free Cash Flow
17M
-8.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-408.6%
Debt / Equity
-4.76x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.